- Major market movements today were dominated by significant corporate news and currency market developments, with particular focus on the healthcare and technology sectors. The US100 led the decline, down 0.72% amid pressure in the technology sector. The US500 fell 0.26%, while the US30 slid 0.50%.
- European markets also traded mostly lower, with the W20 showing the steepest decline (-1.67%) among major European indices. The ITA40 fell 0.78%, while the UK100 managed to stay barely positive (+0.04%). The DE40 and FRA40 declined 0.45% and 0.21% respectively.
- Moderna (MRNA.US) experienced a dramatic 23% decline after substantially reducing its 2025 revenue guidance to $1.5-2.5 billion, down from the previous $2.5-3.5 billion forecast. The company announced aggressive cost-cutting measures, including $1 billion in reductions for 2025 and an additional $500 million in 2026, responding to weakening Covid vaccine demand.
- In tech sector developments, Apple (AAPL) faces mounting challenges as iPhone sales declined 5% in Q4, with global market share dropping to 18%. The company's delayed AI rollout, particularly in China, has impacted performance. Additionally, Apple confronts legal challenges in the UK regarding App Store practices and increased EU scrutiny over new developer fee structures.
- The Biden administration's new AI export controls significantly affected Nvidia (NVDA), whose shares fell 3.7%. While 18 close allies received exemptions, over 120 countries face new restrictions requiring government approval for AI model exports and overseas computing facilities.
- ECB’s Villeroy commented on the French budget puzzle, stating that France is not at risk of not being able to finance itself. He added that French GDP growth could pick up in 2026 and 2027.
- NY Fed’s 3-year expected inflation rose in December to 3% (previously: 2.6%)
- In major M&A news, Johnson & Johnson (JNJ) announced a $14.6 billion acquisition of Intra-Cellular Therapies at $132 per share, sending ITCI shares up 35% in premarket trading. The deal strengthens J&J's CNS portfolio with lumateperone and ITI-1284.
- Currency markets saw significant movement as the euro dropped below 1.02, reaching its lowest level since November 2023. The decline intensified following Friday's strong US jobs report, which forced traders to reassess Fed rate cut expectations. Goldman Sachs now forecasts the euro to fall to 0.97 in six months.
- In energy markets, new US sanctions on Russia have raised supply concerns, though Rystad Energy expects Brent crude to remain range-bound around $80 per barrel. Goldman Sachs suggests prices could test $85 per barrel amid the uncertainty.
- Precious metals faced significant pressure across the board, with silver leading the decline (-2.21%), followed by gold (-1.11%). Palladium and platinum also weakened, dropping 0.50% and 0.25% respectively. The sector's weakness comes amid dollar strength and rising Treasury yields.
- Cryptocurrencies trend lower. Bitcoin declines 2.3% to $91,540, while Ethereum slides 7.7% to $2981.
- The market now awaits Wednesday's US CPI data for further insights into the Federal Reserve's policy path, while monitoring the euro's ability to maintain support near parity levels.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
